Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related To Treatment Of Symptoms Of Vulvovaginal Atrophy
QuatRx Pharmaceuticals announced detailed primary endpoint results from a pivotal Phase 3 clinical trial of Ophena(TM) (ospemifene tablets) to treat postmenopausal women with symptoms of vulvovaginal atrophy, a common condition associated with menopause. The study successfully met all four co-primary endpoints.
More: continued here
Filed under: Endocrinology on June 19th, 2008